Elevation Oncology to Present at the SVB Securities Global Biopharma Conference

Rhea-AI Summary

Elevation Oncology, Inc. (Nasdaq: ELEV) announced that Interim CEO Joseph Ferra will present at the SVB Securities Global Biopharma Conference on February 15, 2023, at 4:20 pm ET. The event will feature a live webcast available on the Company's Investor Relations website.

Elevation Oncology focuses on developing selective cancer therapies for patients with significant unmet medical needs. Its lead candidate, EO-3021, aims to target Claudin18.2, delivering a cytotoxic payload directly to cancer cells. The company is advancing EO-3021 into clinical trials in the US across multiple solid tumor indications.

NEW YORK, Feb. 8, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph Ferra, Interim Chief Executive Officer and Chief Financial Officer of Elevation Oncology, will present at SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 4:20 pm ET.

A live webcast and replay of the event will be available on the Events page of the Company's Investor Relations website at https://investors.elevationoncology.com.

About Elevation Oncology, Inc.
Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are rethinking drug development by seeking out innovative, selective cancer therapies that can be matched to a patient's unique tumor characteristics. Our lead candidate, EO-3021, is a potential best-in-class, antibody drug conjugate (ADC) designed to target Claudin18.2, a clinically validated molecular target that can selectively deliver a cytotoxic payload directly to kill cancer cells. We are working to rapidly advance EO-3021 into the clinic in the US across a range of solid tumor indications to demonstrate its potential, as well as exploring other opportunities through new or existing partnerships and business development opportunities to expand our novel oncology pipeline. For more information, visit www.ElevationOncology.com.

Elevation Oncology Investor and Media Contact
Candice Masse, 978-879-7273
Senior Director, Corporate Communications & Investor Relations
cmasse@elevationoncology.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-present-at-the-svb-securities-global-biopharma-conference-301741375.html

SOURCE Elevation Oncology

FAQ

When will Elevation Oncology present at the SVB Securities Global Biopharma Conference?

Elevation Oncology will present on February 15, 2023, at 4:20 pm ET.

Who is presenting for Elevation Oncology at the conference?

Joseph Ferra, Interim CEO and CFO of Elevation Oncology, will present at the conference.

Where can I watch the Elevation Oncology presentation?

The presentation will be available via a live webcast on Elevation Oncology's Investor Relations website.

What is the lead candidate of Elevation Oncology?

The lead candidate of Elevation Oncology is EO-3021, designed to target Claudin18.2 in cancer therapies.

What is the focus of Elevation Oncology's research?

Elevation Oncology focuses on the discovery and development of selective cancer therapies for solid tumors with unmet medical needs.